$53.02
+2.0%GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
Chief Business Officer
Chief Financial Officer
Compensation
$781,500
Chief Growth Officer
Chief Legal Officer
Chief Operating Officer
Chief Precision Medicine Officer
Head of People Strategy
President of Fabric Genomics
President, Chief Executive Officer & Director
Compensation
$1,625,000
During the last 12 months, insiders have purchased $24.63M and sold $67.04M worth of WGS shares, resulting in $42.41M of net selling activity.
519.4K
22.23M
13.1K
951.83K
+21.3M
+$21.28M
29.2K
2.40M
5.9K
873.15K
+1.5M
+$1.53M
0
0.00
17.2K
2.19M
-2.2M
-$2.19M
0
0.00
532.2K
63.03M
-63.0M
-$63.03M
Casdin Capital, Llc
Director, 10 Percent Owner:
$21.46M
Meister Keith A.
Director, 10 Percent Owner:
$3.17M
Casdin Capital, Llc
Director, 10 Percent Owner:
$60.45M
Stueland Katherine
Director, Officer: Chief Executive Officer
$4.04M
Feeley Kevin
Officer: Chief Financial Officer
$2.00M
Ruch Joshua
Director
$319K
Ryan Jason
Director
$149K
Negative insider sentiment with $42.41M net selling. Selling notably exceeds buying, warranting closer scrutiny of company fundamentals.
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
5 insider sellers vs. 2 buyers. Widespread selling across multiple insiders may signal concerns.
WGS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 30, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 30, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 29, 2024 | December 31, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2023 | December 31, 2022 | 2022 | |
DEF 14A DEF 14A 2023 N/A | March 31, 2023 | April 14, 2023 | 2023 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.